Market Research Logo

Diabetes and Diabetic Complications: Major World Markets, 2nd Edition

The current market for diabetes products is large and growing. Both monitoring and therapeutic products have an excellent market outlook. Diabetes markets have long had major areas of unmet need, and that has not changed during the past several decades. In fact, the number of diabetic patients, especially in the United States, will increase at an accelerating rate over the next 20 years. With the recognition of diabetes as a public health issue of increasing importance, greater pressure will be placed on the medical products industry to satisfy those needs.

So significant is the market opportunity that young companies—many small biopharmaceutical firms—are springing up to meet this challenge, dedicating their entire R&D efforts to diabetes alone. New technologies and drug classes for the treatment of diabetes are being developed, as are methods of diabetes prevention for at-risk populations. It is a market brimming with opportunities and seeing increasing competition for those opportunities.

In such a dynamic marketplace, an understanding of the players and the playing field is an absolute necessity for any company active in diabetes product development, manufacture, and marketing. This completely revised and re-researched edition of Kalorama’s popular 2002 report is intended to provide the pertinent information vital to the serious competitors in the diagnostic and therapeutic diabetes marketplace.

This study considers diagnostics and therapeutics for diabetes type 1 and type 2, as well as the therapeutic markets for several long-term complications of diabetes including hypertension, dyslipidemia, cardiovascular disease, and vascular disorders (retinopathic, neuropathic, renal, and podiatric). The study details the top seven world markets in terms of epidemiology, market potential, and clinical and business trends. In addition new technologies are reviewed and competitors are profiled. Major conclusions of the study are presented with strategic implications and recommendations.

For this edition, a completely new chapter on nutritional and herbal supplementation approaches to diabetes examines the market presence of these new alternative products and their impact on traditional markets.


CHAPTER ONE: EXECUTIVE SUMMARY

  • Background
  • Scope and Methodology
  • Size and Growth of Market
  • The Nature of the Industry
  • The New Technologies
  • Market Trends

CHAPTER TWO: INTRODUCTION

  • The Pathology of Diabetes and Its Complications
    • Diabetes
      • Type I Diabetes
      • Type II Diabetes
      • Gestational Diabete<,/UL>
      • Long-Term Complications
        • Hypertension
        • Dyslipidemia
        • Cardiovascular Disease
        • Vascular Complications
        • Diabetic Retinopathy
        • Renal Complications
        • Neuropathies
        • Diabetic Foot

    • Epidemiology
      • France
      • Germany
      • Italy
      • Japan
      • Spain
      • United Kingdom
      • United States

    CHAPTER THREE: DIABETES MONITORING

    • Background
    • Glucose Monitoring
      • Animas Corp.
      • Argose Inc.
      • Biocontrol Technology Inc.
      • CIBA Vision
      • CME Telemetrix Inc.
      • DexCom Inc.
      • Diabetech Ltd. Co.
      • Diabetex International Corp.
      • Fluent Biomedical Corp.
      • Foviopitics Inc.
      • GlucoLight Corporation
      • Glucon Medical Ltd.
      • Gluko MediTech AG
      • GluMetrics LLC
      • GlySens Inc.
      • Hitachi Ltd.
      • HypoGuard USA Inc.
      • Infratec Inc.
      • InLight Solutions Inc.
      • Institut für Chemo- und Biosensorik
      • Integrity Applications
      • International Diagnostic Technologies Inc. (IDT)
      • iSense Corp
      • Kumetrix Inc.
      • LifeTrac Systems Inc.
      • LighTouch Medical Inc.
      • MedOptix Inc.
      • MicroSense International LLC
      • Mystic Medical Devices (MMD)
      • OptiScan Biomedical Corp.
      • OrSense Ltd.
      • Pelikan Technologies Inc.
      • Pendragon Medical Ltd.
      • Phoenix Bioscience
      • Pindi Products
      • PowderChek Diagnostics
      • PreciSense
      • Sensors for Medicine and Science Inc. (SMSI™)
      • Sensys Medical
      • Sontra Medical Inc.
      • SpectRx Inc.
      • Synthetic Blood International
      • TecMed Inc.
      • TheraSense Inc.
      • Visionary Medical Products Corporation

    • Hemoglobin A1C (HbA1C)
    • Ketone Monitoring
    • Microalbumin Monitoring

    CHAPTER FOUR: CURRENT THERAPEUTIC APPROACHES

    • Background
    • Therapeutic Practices
      • France
        • Diabetes
        • Complications

      • Germany
        • Diabetes
        • Complications

      • Italy
        • Diabetes
        • Complications3

      • Japan
        • Diabetes
        • Complication

      • Spain
        • Diabetes
        • Complications

      • United Kingdom
        • Diabetes
        • Complications

      • United States
        • Diabetes
        • Complications

    • Current Therapeutics for Diabetes
      • Insulin
      • Oral Hypoglycemics
        • Sulfonylureas
        • Biguanides
        • α-Glucosidase Inhibitors
        • Thiazolidinediones
        • Meglitinides
        • D-Phenylalanine Derivatives

    • Current Therapeutics for Diabetic Complications
      • Antihypertensive Therapy
        • ACE Inhibitors
        • α/β(Alpha/Beta)-Blockers
        • Calcium Channel Blockers
        • Diuretics
        • Angiotensin II Receptor Antagonists

      • Dyslipidemia Therapy
      • Atherosclerosis Therapy
      • Arrhythmia Therapy
      • Peripheral Vascular Disease Therapy

    CHAPTER FIVE: MONITORING AND THERAPEUTICS MARKETS

    • Background
    • Market Status and Segmentation
      • Monitoring
      • Therapeutics
        • Insulin
        • Oral Hypoglycemics

      • Diabetic Complication Drugs

    • Geographic Markets
      • France
      • Germany
      • Italy
      • Japan
      • Spain
      • United Kingdom
      • United States

    CHAPTER SIX: NUTRITIONAL SUPPLEMENT AND HERBAL APPROACHES TO THE TREATMENT OF DIABETES

    • Background
    • Nutritional Supplements
      • Ascorbic Acid (Vitamin C)
      • Biotin
      • Chromium
      • Copper
      • Magnesium
      • Niacin and Niacinamide
      • Potassium
      • Selenium
      • Thiamine
      • Vanadium
      • Vitamin B6
      • Vitamin B12
      • Vitamin E
      • Zinc

    • Nutritional Treatment of Diabetic Neuropathy
    • Herbal Treatment of Diabetes
      • Aloe (Various)
      • Arctium lappa (Burdock Root)
      • Allium cepa (Onion)
      • Grifola frondosa (Maitake Mushroom)
      • Mulberry
      • Panax ginseng (Korean ginseng)

    • Ayurvedic Medicine and Herbs
      • Gymnema sylvestre (Asclepias germinata)
      • Momordica charantia (Bitter Gourd)
      • Trigonella foenum graecum (Fenugreek)

    • Other herbs with Significant Anti-Diabetic Effects
    • Traditional Chinese Medicine

    CHAPTER SEVEN: FORWARD-LOOKING TECHNOLOGIES

    • Background
    • Beta-Cell Transplantation Research
    • Research Activities

    CHAPTER EIGHT: COMPANY PROFILES

    • Abbott Laboratories
    • Abgenix, Inc.
    • Alkermes
    • Amylin Pharmaceuticals
    • AstraZeneca
    • Aventis Pharma US Division of Aventis
    • The Bayer Group (USA) Subsidiary of Bayer AG
    • BresaGen Limited
    • Bristol-Myers Squibb
    • Calyx Therapeutics Inc.
    • Diabetogen Biosciences, Inc.
    • GlaxoSmithKline
    • Eli Lilly & Co.
    • Metabolex, Inc.
    • MitoKor
    • Neurocrine Biosciences
    • Novo Nordisk
    • O.S.I. Pharmaceuticals
    • Pfizer Inc.
    • Takeda Pharmaceuticals North America
    • Telik, Inc.
    • Transition Therapeutics, Inc.

    CHAPTER NINE: CONCLUSIONS AND STRATEGIC IMPLICATIONS

    • First Conclusion
      • Implications:

    • Second Conclusion
      • Implications:

    • Third Conclusion
      • Implications:

    • Fourth Conclusion
      • Implications:

    • Fifth Conclusion
      • Implications:

    • Sixth Conclusion
      • Implications:

    • Seventh Conclusion
      • Implications:

    • Eighth Conclusion
      • Implications:

    • Ninth Conclusion
      • Implications:

    • Tenth Conclusion
      • Implications:

    • Eleventh Conclusion
      • Implications:

    • Twelfth Conclusion
      • Implications:

    • Thirteenth Conclusion
      • Implications:

    • Fourteenth Conclusion
      • Implications:

    • Fifteenth Conclusion
      • Implications:

    • Sixteenth Conclusion
      • Implications:

    • Seventeenth Conclusion Implications:

    APPENDIX A: GLOSSARY
    APPENDIX B: COMPANY DIRECTORY

    LIST OF EXHIBITS

    CHAPTER ONE:EXECUTIVE SUMMARY

    • Figure 1-1: Diagnosed Diabetes Cases in the Seven Major World Healthcare Markets: 2004-2014
    • Figure 1-2: Trending in the World’s Major Blood Glucose Monitoring Markets (Total): 2004 - 2014
    • Table 1-1: Estimated Market Sizes for Insulin in the Seven Major World Healthcare Markets: 2004 - 2014
    • Table 1-2: Estimated Market Sizes for Oral Hypoglycemics in the Seven Major World Healthcare Markets: 2004 - 2014
    • Table 1-3: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets by Complication 2004 - 2014

    CHAPTER TWO: INTRODUCTION

    • Table 2-1: Characteristics of Type I and Type II Diabetes Mellitus
    • Table 2-2: Common Symptoms and Conditions of Diabetes Mellitus
    • Table 2-3: Prevalence Rates and Cases for All Diabetes Mellitus in the Seven Major World Healthcare Markets: 2001
    • Table 2-4: Incidence and Prevalence of Type I Diabetes in the Seven Major World Healthcare Markets 2001
    • Table 2-5: Prevalence of Diabetes in the Seven Major World Healthcare Markets by Type 2004-2014
    • Figure 2-1: Trending in the Total Prevalence of Diabetes Cases and the General Population in the Seven Major World Healthcare Markets: 2004-2014
    • Figure 2-2: Composition of the Diabetes Patient Population in the Seven Major World Healthcare Markets: 2004 and 201464
    • Figure 2-3: Geographic Distribution of the Diabetes Patient Population: 2004, 2009, 2104
    • Figure 2-4: Geographic Distribution of the Type I Patient Population: 2004, 2009, 2104
    • Figure 2-5: Geographic Distribution of the Type II Patient Population: 2004, 2009, 2104
    • Figure 2-6: Population Trends in the Seven Major World Healthcare Markets: 2004-2014
    • Table 2-7: The Prevalence of Diabetes in France: 2004-2014
    • Table 2-8: The Prevalence of Diabetes in Germany: 2004-2014
    • Table 2-9: The Prevalence of Diabetes in Italy: 2004-2014
    • Table 2-10: The Prevalence of Diabetes in Japan: 2004-2014
    • Table 2-11: The Prevalence of Diabetes in Spain: 2004-2014
    • Figure 2-12: The Prevalence of Diabetes in the United Kingdom: 2004-2014
    • Table 2-13: The Prevalence of Diabetes in the United States: 2004-2014

    CHAPTER THREE: DIABETES MONITORING

    • Table 3-1: Key Glucose Monitoring Products on the Market
    • Table 3-2: Key HbA1C Monitors and Test Kits
    • Table 3-3: Key Ketone Monitoring Products on the Market
    • Table 3-4: Key Microalbumin Monitoring Products on the Market

    CHAPTER FOUR: CURRENT THERAPEUTIC APPROACHES

    • Table 4-1: Estimated Number of Preventable Diabetes Cases and Complications in the United States
    • Table 4-2: Key Insulin Products for the Treatment of Diabetes
    • Table 4-3: Key Oral Hypoglycemics for the Treatment of Type II Diabetes
    • Table 4-4: Common ACE Inhibitors on the Market for Diabetic Hypertension
    • Table 4-5: Common Adrenergic Receptor (α and β) on the Market for Diabetic Hypertension
    • Table 4-6: Common Calcium Channel Blockers on the Market for Diabetic Hypertension
    • Table 4-7: Common Combined Diuretic Products on the Market for Diabetic Hypertension
    • Table 4-8: Common Angiotensin II Receptor Antagonists on the Market for Diabetic Hypertension
    • Table 4-9: Commonly Used Antilipemic Agents on the Market for Diabetic Dyslipidemia
    • Table 4-10: Vaughn Williams Classification of Anti-Arrhythmic Drugs
    • Table 4-11: Common Antiarrhythmatic Drugs
    • Table 4-12: Drugs Commonly Used to Combat Diabetic Peripheral Vascular Disease

    CHAPTER FIVE: DIABETES MONITORING AND THERAPEUTICS MARKETS

    • Table 5-1: Estimated Market Sizes for Blood Glucose Monitoring Equipment and Supplies in the Seven Major World Healthcare Markets 2004-2014
    • Figure 5-1: Trending in the World’s Major Blood Glucose Monitoring Markets (Total): 2004-2014
    • Figure 5-2: Distribution of the World’s Major Blood Glucose Monitoring Markets by Country: 2004 / 2009 / 20014
    • Figure 5-3: Estimated Market Shares of the Key Participants in the Seven Major World’s Markets for Glucose Monitoring Products: 2004
    • Table 5-2: Estimated Market Sizes for Insulin in the Seven Major World Healthcare Markets 2004-2014
    • Figure 5-4: Trending in the World’s Major Markets for Insulin 2004 - 2014
    • Figure 5-5: Market Distribution in the World’s Major Markets for Insulin 2004 - 2014
    • Figure 5-6: Estimated Insulin Market Shares in the Seven Major World Healthcare Markets: 2004
    • Table 5-3: Estimated Market Sizes for Oral Hypoglycemics in the Seven Major World Healthcare Markets 2004-2014
    • Figure 5-7: Trending in the World’s Major Markets for Oral Hypoglycemic Drugs 2004 - 2014
    • Figure 5-8: Market Distribution in the World’s Major Markets for Oral Hypoglycemics 2004 - 2014
    • Figure 5-9: Estimated Oral Hypoglycemic Drug Market Shares in the Seven Major World Healthcare Markets: 2004
    • Table 5-4: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets by Complication Type (Hypertension, Hyperlipidemia, Arrhythmias, Peripheral Vascular Disease) 2004 - 2014
    • Figure 5-10: Trending in the Total World’s Major Markets for Drugs to Treat Diabetic Complications (by Complication): 2004 - 2014
    • Figure 5-11: Composition of the Total World’s Major Markets for Drugs to Treat Diabetic Complications (by Complication): 2004 - 2014
    • Table 5-5: Estimated Diabetes-Care Market Size in France by Segment (Testing, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2004 - 2014
    • Figure 5-12: Trending in the French Market for Diabetes-Care Products by Product Class 2004 - 2014
    • Figure 5-13: Composition of the French Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Table 5-6: Estimated Diabetes-Care Market Size in Germany by Segment (Testing, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2004 - 2014
    • Figure 5-14: Trending in the German Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Figure 5-15: Composition of the German Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Table 5-7: Estimated Diabetes-Care Market Size in Italy by Segment (Testing, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2004 - 2014
    • Figure 5-16: Trending in the Italian Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Figure 5-17: Composition of the Italian Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Table 5-8: Estimated Diabetes-Care Market Size in Japan by Segment (Testing, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2004 - 2014
    • Figure 5-18: Trending in the Japanese Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Figure 5-19: Composition of the Japanese Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Table 5-9: Estimated Diabetes-Care Market Size in Spain by Segment (Testing, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2004 - 2014
    • Figure 5-20: Trending in the Spanish Market for Diabetes-Care Products by Product Class: 2004 - 2013
    • Figure 5-21: Composition of the Spanish Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Table 5-10: Estimated Diabetes-Care Market Size in the United Kingdom by Segment (Testing, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2004 - 2014
    • Figure 5-22: Trending in the United Kingdom Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Figure 5-23: Composition of the United Kingdom Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Table 5-11: Estimated Diabetes-Care Market Size in the United States by Segment (Testing, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2004 - 2014
    • Figure 5-24: Trending in the United States Market for Diabetes-Care Products by Product Class: 2004 - 2014
    • Figure 5-25: Composition of the United States Market for Diabetes-Care Products by Product Class: 2004 - 2014

    CHAPTER SEVEN: FORWARD-LOOKING TECHNOLOGIES

    • Table 7-1: Recently Introduced Diabetes-Designated Products
    • Table 7-2: Products in Development for Diabetes and Diabetic Complications

  • Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report